Mablink Bioscience Enters an Agreement to be Acquired by Lilly The pending acquisition reflects the potential of Mablink’s existing pipeline and proprietary PSARLink™ technology for development of additional drug conjugates. Lyon, France – October 18, 2023 -...

Mablink Bioscience appoints Pejvack Motlagh, M.D., as Chief Medical Officer Mablink Bioscience appoints Pejvack Motlagh, M.D., as Chief Medical Officer Lyon - France, June 15, 2023 (08h00 CEST) Mablink Bioscience (“Mablink”), a biotechnology company dedicated to advancing...

Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with significant tumor growth inhibition in multiple...